vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and ORION ENERGY SYSTEMS, INC. (OESX). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $21.1M, roughly 1.6× ORION ENERGY SYSTEMS, INC.). On growth, ORION ENERGY SYSTEMS, INC. posted the faster year-over-year revenue change (7.7% vs -23.8%). ORION ENERGY SYSTEMS, INC. produced more free cash flow last quarter ($-1.1M vs $-47.7M). Over the past eight quarters, Ginkgo Bioworks Holdings, Inc.'s revenue compounded faster (-6.2% CAGR vs -10.6%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

Orion Energy Systems, Inc. is an American LED lighting and intelligent controls enterprise, founded in Plymouth, Wisconsin, and headquartered in Manitowoc, Wisconsin

DNA vs OESX — Head-to-Head

Bigger by revenue
DNA
DNA
1.6× larger
DNA
$33.4M
$21.1M
OESX
Growing faster (revenue YoY)
OESX
OESX
+31.5% gap
OESX
7.7%
-23.8%
DNA
More free cash flow
OESX
OESX
$46.5M more FCF
OESX
$-1.1M
$-47.7M
DNA
Faster 2-yr revenue CAGR
DNA
DNA
Annualised
DNA
-6.2%
-10.6%
OESX

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
DNA
DNA
OESX
OESX
Revenue
$33.4M
$21.1M
Net Profit
$160.0K
Gross Margin
30.9%
Operating Margin
-211.9%
1.8%
Net Margin
0.8%
Revenue YoY
-23.8%
7.7%
Net Profit YoY
110.6%
EPS (diluted)
$-1.41
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
OESX
OESX
Q4 25
$33.4M
$21.1M
Q3 25
$38.8M
$19.9M
Q2 25
$49.6M
$19.6M
Q1 25
$48.3M
$20.9M
Q4 24
$43.8M
$19.6M
Q3 24
$89.0M
$19.4M
Q2 24
$56.2M
$19.9M
Q1 24
$37.9M
$26.4M
Net Profit
DNA
DNA
OESX
OESX
Q4 25
$160.0K
Q3 25
$-80.8M
$-581.0K
Q2 25
$-60.3M
$-1.2M
Q1 25
$-91.0M
$-2.9M
Q4 24
$-1.5M
Q3 24
$-56.4M
$-3.6M
Q2 24
$-217.2M
$-3.8M
Q1 24
$-165.9M
$1.6M
Gross Margin
DNA
DNA
OESX
OESX
Q4 25
30.9%
Q3 25
31.0%
Q2 25
30.1%
Q1 25
27.4%
Q4 24
29.4%
Q3 24
23.1%
Q2 24
21.6%
Q1 24
25.8%
Operating Margin
DNA
DNA
OESX
OESX
Q4 25
-211.9%
1.8%
Q3 25
-231.8%
-1.2%
Q2 25
-132.1%
-5.2%
Q1 25
-184.1%
-12.7%
Q4 24
-236.3%
-6.4%
Q3 24
-62.0%
-16.9%
Q2 24
-396.7%
-17.2%
Q1 24
-469.1%
6.8%
Net Margin
DNA
DNA
OESX
OESX
Q4 25
0.8%
Q3 25
-207.9%
-2.9%
Q2 25
-121.6%
-6.4%
Q1 25
-188.2%
-13.9%
Q4 24
-7.7%
Q3 24
-63.3%
-18.7%
Q2 24
-386.4%
-18.9%
Q1 24
-437.3%
6.1%
EPS (diluted)
DNA
DNA
OESX
OESX
Q4 25
$-1.41
$0.04
Q3 25
$-1.45
$-0.17
Q2 25
$-1.10
$-0.04
Q1 25
$-1.68
$1.32
Q4 24
$-1.91
$-0.46
Q3 24
$-1.08
$-1.10
Q2 24
$-4.23
$-0.12
Q1 24
$-3.32
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
OESX
OESX
Cash + ST InvestmentsLiquidity on hand
$422.6M
$4.7M
Total DebtLower is stronger
$9.8M
Stockholders' EquityBook value
$508.6M
$11.8M
Total Assets
$1.1B
$48.3M
Debt / EquityLower = less leverage
0.83×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
OESX
OESX
Q4 25
$422.6M
$4.7M
Q3 25
$495.5M
$5.2M
Q2 25
$559.4M
$3.6M
Q1 25
$325.3M
$6.0M
Q4 24
$561.6M
$7.5M
Q3 24
$616.2M
$5.4M
Q2 24
$730.4M
$5.7M
Q1 24
$840.4M
$5.2M
Total Debt
DNA
DNA
OESX
OESX
Q4 25
$9.8M
Q3 25
$9.9M
Q2 25
$8.5M
Q1 25
$10.3M
Q4 24
Q3 24
$12.5M
Q2 24
$13.5M
Q1 24
$10.0M
Stockholders' Equity
DNA
DNA
OESX
OESX
Q4 25
$508.6M
$11.8M
Q3 25
$559.8M
$11.4M
Q2 25
$613.0M
$10.8M
Q1 25
$647.4M
$11.9M
Q4 24
$716.1M
$14.5M
Q3 24
$797.9M
$15.8M
Q2 24
$833.1M
$19.1M
Q1 24
$987.3M
$22.5M
Total Assets
DNA
DNA
OESX
OESX
Q4 25
$1.1B
$48.3M
Q3 25
$1.2B
$47.9M
Q2 25
$1.2B
$49.0M
Q1 25
$1.3B
$52.5M
Q4 24
$1.4B
$52.7M
Q3 24
$1.5B
$56.3M
Q2 24
$1.6B
$59.8M
Q1 24
$1.6B
$63.2M
Debt / Equity
DNA
DNA
OESX
OESX
Q4 25
0.83×
Q3 25
0.87×
Q2 25
0.79×
Q1 25
0.87×
Q4 24
Q3 24
0.79×
Q2 24
0.71×
Q1 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
OESX
OESX
Operating Cash FlowLast quarter
$-47.7M
$-897.0K
Free Cash FlowOCF − Capex
$-47.7M
$-1.1M
FCF MarginFCF / Revenue
-142.8%
-5.4%
Capex IntensityCapex / Revenue
0.0%
1.2%
Cash ConversionOCF / Net Profit
-5.61×
TTM Free Cash FlowTrailing 4 quarters
$-905.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
OESX
OESX
Q4 25
$-47.7M
$-897.0K
Q3 25
$-31.6M
$1.8M
Q2 25
$-40.3M
$-515.0K
Q1 25
$-51.5M
$-699.0K
Q4 24
$-42.4M
$3.8M
Q3 24
$-103.5M
$498.0K
Q2 24
$-84.4M
$-3.0M
Q1 24
$-89.3M
$175.0K
Free Cash Flow
DNA
DNA
OESX
OESX
Q4 25
$-47.7M
$-1.1M
Q3 25
$1.6M
Q2 25
$-40.3M
$-570.0K
Q1 25
$-59.1M
$-750.0K
Q4 24
$-56.1M
$3.7M
Q3 24
$-118.6M
$493.0K
Q2 24
$-111.4M
$-3.0M
Q1 24
$-96.0M
$144.0K
FCF Margin
DNA
DNA
OESX
OESX
Q4 25
-142.8%
-5.4%
Q3 25
7.9%
Q2 25
-81.2%
-2.9%
Q1 25
-122.4%
-3.6%
Q4 24
-128.0%
19.1%
Q3 24
-133.2%
2.5%
Q2 24
-198.2%
-15.0%
Q1 24
-252.9%
0.5%
Capex Intensity
DNA
DNA
OESX
OESX
Q4 25
0.0%
1.2%
Q3 25
0.0%
1.3%
Q2 25
0.1%
0.3%
Q1 25
15.8%
0.2%
Q4 24
31.3%
0.1%
Q3 24
16.9%
0.0%
Q2 24
48.1%
0.1%
Q1 24
17.7%
0.1%
Cash Conversion
DNA
DNA
OESX
OESX
Q4 25
-5.61×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

OESX
OESX

Lighting Product And Installation$11.9M56%
Electric Vehicle Charging Systems$4.7M22%
Maintenance Services$4.4M21%

Related Comparisons